UTHR

In March 2026, the TETON-1 study for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing meaningful improvement in forced vital capacity (FVC). In April 2026, United Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for miroliverELAP® for the treatment of acute liver failure. On May 6, 2026, United Therapeutics reported its first-quarter 2026 financial results, which missed analyst expectations. In May 2026, UBS raised its price target for United Therapeutics to $705, citing pipeline catalysts and FDA progress. On April 29, 2026, the company announced the retirement of Professor Raymond Dwek from its Board of Directors. Over the last 12 months, the stock price has increased by 85.01%, with a year-to-date return of 16.81%.